Part 1
A majority of patients with multiple sclerosis in Canada are advised to start treatment with a disease-modifying therapy, most commonly with an anti-CD20 treatment, according to the results of a recent survey on NeuroSens. The survey was conducted from 27 February-31 March 2025 and received 64 responses from MS neurologists and nurses. Read More
Webinar on recent adjunctive antiseizure medications with an emphasis on the use of cenobamate for focal epilepsies and fenfluramine for Dravet syndrome. Read More
The newly-published Discontinuing Disease-modifying Therapies in Stable Relapsing-onset Multiple Sclerosis (DOT-MS) is the second important trial to examine the feasibility of discontinuing disease-modifying therapy (DMT) in patients with multiple sclerosis (Coerver et al. JAMA Neurol 2025;82:123-131). Read More
Click here to watch Dr. Lisa Sabella discuss the case and the responses to the survey.
R.M. is a 24-year-old woman who works at a daycare centre. She is referred from the emergency room because of a two-week history of paresthesiae in both legs and the mid and lower trunk. She is not aware of any weakness. There is no bladder disturbance. She has a subjective mid truncal sensory level. Prior history includes a Bell’s palsy three years ago which was painless and resolved without treatment in 3-4 weeks. Read More